Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.37 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16320526 | 0.90 | SLC6A4 (0.34) | SLC6A4SLC6A3SLC6A2HDAC1HDAC2 | |
| SCHEMBL3914232 | 0.90 | CSF1R (0.36) | CSF1RKITSLC6A4SLC6A3SLC6A2 | |
| SCHEMBL5481061 | 0.83 | CSF1R (0.38) | CSF1RKIT | |
| SCHEMBL16320263 | 0.82 | CSF1R (0.37) | CSF1RKITHDAC1HDAC2 | |
| Acetic Acid SCHEMBL5471957 | 0.82 | CSF1R (0.37) | CSF1RKITHDAC1HDAC2 | |
| SCHEMBL5474035 | 0.81 | SLC6A4 (0.37) | SLC6A4SLC6A3 | |
| SCHEMBL16320525 | 0.79 | SLC6A4 (0.35) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL14374989 | 0.76 | CSF1R (0.52) | CSF1RKIT | |
| SCHEMBL16320568 | 0.76 | CSF1R (0.37) | CSF1RKIT | |
| SCHEMBL17416788 | 0.74 | CSF1R (0.39) | CSF1RKITSLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394289-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-19 | — | — | US | disclosed |
| EP-2016070-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-13 | — | — | EP | disclosed |
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-25 | — | — | US | disclosed |
| US-8859602-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CSF1R 59/4885KIT 108/4885SLC6A4 3756/4885 |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CSF1R 59/4885KIT 108/4885SLC6A4 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.